Introduction
Coronary artery disease (CAD), including myocardial infarction, is the leading cause of death and disability in the world. [1] [2] [3] One of the standard treatments for CAD is percutaneous coronary intervention (PCI) with stent placement 4 ; however, a portion of the patients with PCI treatment suffer in-stent restenosis (ISR), which is the main limitation of coronary stenting. 5 ISR is the formation of scar tissue over the stent and can cause the opened artery to narrow again. Although the incidence of was ISR reduced recently with the application of new therapies, treatment of ISR remains a challenging clinical issue. 6 During the past decade, there has been increasing scientific interest in understanding the complex relationship between coronary restenosis after PCI and the Association of ACE insertion or deletion polymorphisms with the risk of coronary restenosis after percutaneous coronary intervention: A meta-analysis renin-angiotensin system (RAS). [7] [8] [9] The RAS plays an important role in blood pressure and cardiovascular homeostasis 10, 11 ; and recently-published data indicate that angiotensin II, the main biologically-active peptide of RAS, contributes to coronary restenosis development and progression. 12, 13 The production of angiotensin II is regulated by ACE, which has serum levels governed by genetic variation at the ACE locus. Previous studies indicate that certain genetic polymorphisms are recognized to be associated with the risk of coronary restenosis. [14] [15] [16] [17] [18] [19] Among these genes, the ACE gene polymorphisms were considered as a risk factor of coronary restenosis in several published papers [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] ; however, the results of these studies were inconsistent. Rebrova et al. 34 found that ACE genetic polymorphism is associated with coronary restenosis risk. Guneri et al. 32 and Okumura et al. 33 also confirmed the previous studies; however, Martínez-Ríos et al. 35 did not find any association between ACE gene insertion/deletion (I/D) polymorphisms and coronary restenosis risk. Therefore, we collected all published case-control studies related to the ACE I/D polymorphisms and coronary restenosis risk to perform a meta-analysis, to further explore the relationship between ACE gene polymorphisms and coronary restenosis.
Materials and methods

Literature collection and screening
We identified all the articles that reported the association of ACE polymorphisms and coronary restenosis risk. We conducted a computerized literature search of PubMed, EMBase, the Chinese Biomedical Literature Database, the Chinese CNKI, and the Wanfang database; using the terms 'coronary restenosis' and 'angiotensin-converting enzyme' or 'ACE', and 'polymorphism' or single nucleotide polymorphism ('SNP'), or 'genotype', or 'insertion/deletion' or 'I/D', or 'D/I', 'D/D' or 'I/I'; without any restriction on language or publication year. We expected that the included studies must meet to the following criteria: Literature were excluded if relevant data were not available or there was heterogeneity of gene polymorphisms in the control population.
Quality assessment and data extraction
Two reviewers (H-W Miao and H Gong) used a standard approach, according to the above-mentioned inclusion criteria, independently evaluating the studies and extracting the data (Table 1 ). Discrepancies were resolved through discussion. The methodological quality of the included studies was assessed by using the Cochrane Handbook 5.2 36 quality evaluation criteria. We extracted the following information for each study: The first author's last name, year of publication, ethnicity of the study participants, numbers of cases and controls, and frequency of insertion or deletion genotypes. Hardy-Weinberg equilibrium was assessed, using the χ 2 test. 
Statistical analysis
We used RevMan 5.2 software, provided by the Cochrane Collaboration, to perform the meta-analysis. We used Q-test and I 2 test to examine the heterogeneity between each study. The odds ratio (OR) and its 95% CI were utilized for efficacy analysis statistics. We selected either the fixed or random-effects model, to merge the OR according to the I 2 value. Sensitivity analyses and publication bias tests were performed according to previous literature. We considered a P < 0.05 as a significant difference.
Results
Study identification
As shown in Figure 1 , we preliminarily detected 144 articles in the literature: 104 were excluded, because of only gene expression analysis not relevant to coronary restenosis, and no ACE genotype data; and 24 studies were further excluded because of being only a review paper, no control group, and/or being duplicate publications. Therefore, a total of 16 journal literature articles, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] with a total of 4693 subjects (1241 patients with coronary restenosis and 3452 subjects without coronary restenosis), were included in this research.
Quantitative synthesis
As shown in Figure 2 , the heterogeneity test of the various studies revealed there were heterogeneous results (I 2 = 77%; p < 0.0001); therefore, we used the random effects model in our analysis. We found a significant difference between ACE I/D polymorphisms and the risk for coronary restenosis. The D allele carriers had a 1.92-fold increased risk for coronary restenosis, compared to the I allele carriers (OR = 1.92; 95% CI 1.40-2.63; p < 0.001). Also, subgroup analysis by stratification according to ethnicity (Figure 3 ) showed that this association was found not only in the Caucasian population ((D allele versus I allele: OR = 1.94; 95% CI (1.38-2.80); p < 0.001)), but also in the Asian population ((D allele versus I allele: OR = 1.83; 95% CI (1.05-3.20); p = 0.03)). After stratification according to age (Figure 4 ), we found that D allele carriers have a higher risk for development of coronary restenosis in subjects < 60 years old (OR = 2.13; 95%CI: 1.40-3.24; p = 0.0004); while in subjects with ⩾ 60 years of age, the association was present at a borderline significance (OR = 1.48; 95%CI: 0.98-2.25; p = 0.06).
Publication bias analysis
RevMan 5.0 software was used to analyze the publication bias; a funnel plot ( Figure 5 ) showed that the points were evenly distributed and symmetrical, and most of the points were within the 95% CI. The shape of the funnel plots showed no obvious asymmetry. The result of Egger's test did not show statistical evidence for bias. It indicated that there was no publication bias and that the result of the study is credible.
Sensitivity analysis
We deleted one single study from the overall pooled analysis each time, to check the influence of the removed data set to the overall ORs. The pooled ORs and 95% CIs were not significantly altered when any part of the study was omitted, which indicated that any single study had little impact on the overall ORs. 
Discussion
In the present study, we performed a meta-analysis to evaluate the association of ACE gene I/D polymorphisms with coronary restenosis. We found a significant association of ACE gene polymorphisms with coronary restenosis. Restenosis after PCI is an important clinical problem. The formation of restenosis may result from the following mechanisms:
• • A response to injury of the vessel wall;
• • A platelet aggregation;
• • A thrombus formation;
• • A liberation of growth factors;
• • Cellular hyperplasia involving predominantly smooth muscle proliferation and migration; and • • Intercellular matrix formation.
So far, the etiological basis of restenosis is only partly understood. The genetic polymorphisms in the ACE gene are considered to be associated with coronary restenosis. ACE is a core factor for the production of angiotensin II; and the degradation of bradykinin 37 and angiotensin II plays a pivotal role in the restenosis process. 38 Previous studies indicate that high ACE levels may increase the risk of coronary thrombosis. 39 And ACE gene I/D polymorphisms have consistently been found associated with differential plasma ACE levels. 40 Furthermore, serum plasma activity of ACE is thought to play a major role in the development of restenosis after coronary stent implantation. 41, 42 Recently, a number of articles in the literature reported on the relationship between ACE I/D polymorphisms and coronary restenosis risk [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ; however, the results are inconsistent or even contradictory. This discrepancy may result from the small sample size, ethnic difference, false positive results, and/or study design in each study.
In the present study, we performed a meta-analysis to reveal the association of ACE I/D polymorphisms with coronary restenosis. Our results showed that ACE gene I/D polymorphisms were associated with the susceptibility of coronary restenosis, with the D allele carriers having a 1.92-fold increase in risk for restenosis, compared to the I allele carriers; however, there is still a need for further research and screening of the etiological relationships between the functional polymorphism loci of the ACE gene and the susceptibility to coronary restenosis.
There are still several limitations, when interpreting these results. On the one hand, all the subjects involved in our study are of different ethnicity. On the other hand, the heterogeneity found between each study may result from the different research methods.
In conclusion, the present study suggested that there is an association between the ACE gene I/D polymorphisms and coronary restenosis.
